6 completed. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
Follow Menorrhagia: new trials by email Literature Review of Menorrhagia trials Research Report on Menorrhagia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids Vilaprisan (BAY1002670), Vilaprisan (BAY1002670, Ulipristal - Leiomyoma | Phase 2 | Completed | Bayer | 120 | 2015-06-01 | 2016-11-22 |
| Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) Elagolix placebo, Elagolix, 0.5 mg estradiol / 0.1 mg norethindrone acetate - Heavy Uterine Bleeding, Uterine Fibroids | Phase 2 | Completed | AbbVie | 571 | 2013-04-08 | 2020-07-21 |
| Dexamethasone for Excessive Menstruation Dexamethasone, placebo - Heavy Menstrual Bleeding | Phase 2 | Completed | University of Edinburgh | 123 | 2013-01-01 | 2018-10-25 |
| Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids Elagolix, Placebo, Estradiol/Norethindrone acetate (E2/NETA) - Heavy Uterine Bleeding, Uterine Fibroids | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 271 | 2011-09-08 | 2021-07-13 |
| IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia Oprelvekin, Interleukin 11, IL-11 - Von Willebrand Disease | Phase 2 | Completed | Margaret Ragni | 7 | 2008-01-01 | 2018-01-31 |
| Menorrhagia Study in Women With Treatment-resistant Menorrhagia Asoprisnil (BAY86-5294), Placebo - Menorrhagia | Phase 2 | Completed | Bayer | 26 | 2001-11-01 | 2014-12-30 |
Leiomyoma (3) · von Willebrand Diseases (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Hemorrhage (6) · Menstruation Disturbances (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Urogenital Diseases (6) · Uterine Diseases (6) · Uterine Hemorrhage (6) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Connective and Soft Tissue (3) · Neoplasms, Muscle Tissue (3)
Estradiol (2) · Norethindrone Acetate (2) · elagolix (2) · estradiol, norethindrone drug combination (2) · Dexamethasone (1) · Interleukin-11 (1) · Progesterone (1) · asoprisnil (1) · oprelvekin (1) · ulipristal (1) · vilaprisan (1)
Bayer (2) · AbbVie (1) · AbbVie (prior sponsor, Abbott) (1) · Margaret Ragni (1) · University of Edinburgh (1)
United Kingdom (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Finland (1) · Germany (1) · Hungary (1) · Italy (1) · Lithuania (1) · Netherlands (1) · Norway (1) · Poland (1) · Portugal (1) · Spain (1)
Charlotte Owens, MD (1) · Hilary Critchley, MBChB MD (1) · Margaret V. Ragni, MD, MPH (1)
PMID 21833452, PMID 25588784, PMID 27733082, PMID 30303923, PMID 32559602, PMID 34218053
2014 (1)